Generic molecule
- Qbrexza (glycopyrronium tosylate)
- Glycopyrronium tosylate 2.4%
- Sofdra (sofpironium)
- Sofpironium skin treatment gel 12.45%
·Comparison
Qbrexza vs Sofdra for excessive underarm sweating
Short answer
Both are once-daily prescription treatments for underarm sweating in people age 9 and older. Qbrexza is a cloth. Sofdra is a gel. No trial has compared them head to head.
Side-by-side
| Criterion | Qbrexza (glycopyrronium tosylate) | Sofdra (sofpironium) |
|---|---|---|
| Generic molecule | Glycopyrronium tosylate 2.4% | Sofpironium skin treatment gel 12.45% |
| Drug class design | Quaternary-ammonium sweat-reducing medicine | Soft-drug sweat-reducing medicine (rapidly metabolized after whole-body absorption) |
| Dosage form | Single-use pre-moistened cloth | Gel via metered dispenser |
| Frequency | Once daily | Once daily |
| FDA-approved uses | Primary excessive underarm sweating, age 9+ | Primary excessive underarm sweating, age 9+ |
| Key trials | ATMOS-1, ATMOS-2 | CARDIGAN-1, CARDIGAN-2 |
| Main result measured | Underarm Sweating Daily Diary (ASDD) people who improved rate | HDSM-Ax-7 ≥2-point improvement |
| Body area applicability | Underarm only | Underarm only |
Drug class design
- Qbrexza (glycopyrronium tosylate)
- Quaternary-ammonium sweat-reducing medicine
- Sofdra (sofpironium)
- Soft-drug sweat-reducing medicine (rapidly metabolized after whole-body absorption)
Dosage form
- Qbrexza (glycopyrronium tosylate)
- Single-use pre-moistened cloth
- Sofdra (sofpironium)
- Gel via metered dispenser
Frequency
- Qbrexza (glycopyrronium tosylate)
- Once daily
- Sofdra (sofpironium)
- Once daily
FDA-approved uses
- Qbrexza (glycopyrronium tosylate)
- Primary excessive underarm sweating, age 9+
- Sofdra (sofpironium)
- Primary excessive underarm sweating, age 9+
Key trials
- Qbrexza (glycopyrronium tosylate)
- ATMOS-1, ATMOS-2
- Sofdra (sofpironium)
- CARDIGAN-1, CARDIGAN-2
Main result measured
- Qbrexza (glycopyrronium tosylate)
- Underarm Sweating Daily Diary (ASDD) people who improved rate
- Sofdra (sofpironium)
- HDSM-Ax-7 ≥2-point improvement
Body area applicability
- Qbrexza (glycopyrronium tosylate)
- Underarm only
- Sofdra (sofpironium)
- Underarm only
Which may fit better?
- Patient prefers a discrete, travel-friendly dosage form
- Either works; single-use cloth (Qbrexza) is fully self-contained; gel-with-dispenser (Sofdra) has a small footprint but requires the dispenser.
- Patient has had side effects such as dry mouth, constipation, blurred vision, and trouble urinating with prior medications
- Sofdra's soft-drug design is intended to reduce whole-body exposure. Anecdotally some patients tolerate one better than the other; data are not definitive head-to-head.
- Patient has reasons a treatment may not be safe (Sjögren, BPH, glaucoma)
- Both products list sweat-reducing medicine reasons a treatment may not be safe in their labels. Review the prescribing information for the specific product and discuss with the prescribing clinician.
- Insurance coverage drives the choice
- Formulary coverage and cost-after-coverage vary by payer. Many patients consult the prescribing clinician about manufacturer copay-assistance programs available for both products.
Same use, different forms
Both drugs block a nerve signal that tells sweat glands to work. Qbrexza is a single-use cloth. Sofdra is a measured gel that the body breaks down soon after it leaves the skin.
No head-to-head trial
Qbrexza and Sofdra were tested in separate studies with different symptom scales and inactive treatments. Their response rates cannot be compared as if they came from one trial. Choice often comes down to cloth versus gel, side effects, and the prescriber's judgment.
What's the same
Both are used once a day and only on underarms. Both can cause skin irritation, dry mouth, blurred vision, a widened pupil, constipation, or trouble urinating. Wash your hands after either product.
Frequently asked
- Can I switch from one to the other?
- Yes, patients sometimes switch when one is inadequately effective or poorly tolerated. There is no required washout. The prescribing clinician determines the timing and counsels on what to expect during the transition.
- Is one safer than the other?
- Both are FDA-approved at their respective doses. The soft-drug design of sofpironium is intended to reduce whole-body exposure, but the practical adverse-event profiles overlap substantially. Specific safety considerations (reasons a treatment may not be safe, drug interactions) are in each product's label.
Read each option
·Read next
Keep reading.
Treatments compared
Body areas